Funding round
Kriya Therapeutics Series C
Kriya Therapeutics, which works in gene therapy research and development in Morrisville, raised $270M in a Series C round announced on 16 May 2022, led by Patient Square Capital. 10 firms took part. It is Kriya Therapeutics' first venture round on record.
$270M
Amount raised
Not disclosed
Post-money valuation
10
Investors
1 lead
Valuation
What this round says about the price
Kriya Therapeutics did not disclose a valuation in this round. It is Kriya Therapeutics' first venture round on record, 3 years after it was founded in 2019. It is 46% of the $590M Kriya Therapeutics has raised in the venture rounds on record. Kriya Therapeutics raised again 40 months later: a Series D round of $320M in Sep 2025.
Kriya Therapeutics' funding rounds
Kriya Therapeutics has 2 venture rounds on record. This one is highlighted.
- Series C this round 16 May 2022, led by Patient Square Capital $270M
- Series D 10 Sep 2025, led by Patient Square Capital and Premji Invest $320M
Investors
Who put money in
Patient Square Capital led the round with 9 other firms.
Lead investor
- backs 7 venture-backed companies new investor
Also in the round
- Bluebird Ventures new investor
- backs 4 venture-backed companies new investor
- Dexcel Pharma new investor
- backs 39 venture-backed companies new investor
- backs 15 venture-backed companies new investor
- Lightswitch Capital new investor
- backs 6 venture-backed companies new investor
- QVT new investor
- backs 2 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to hiring, product development, geographic expansion, scaling operations and working capital.
- Hiring
- Product development
- Geographic expansion
- Scaling operations
- Working capital
Comparable rounds
How it compares
46 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $86M, and this round was 3.2 times the median. The closest in time, other companies' Series C rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 31 May 2022 | $55M | not disclosed | Columbus Venture Partners and Caixa Capital Risc |
| Tessera Therapeutics Biotechnology | 19 Apr 2022 | $300M | not disclosed | SoftBank Vision Fund |
| Biotechnology | 12 Apr 2022 | $120M | not disclosed | Deerfield |
| Biotechnology | 13 Jun 2022 | $86M | not disclosed | Earlybird and Andera Partners |
| Biotechnology | 3 Jun 2022 | $85M | not disclosed | Blue Water Life Science Advisors and ARCH Venture Partners |
| Biotechnology | 21 Apr 2022 | $7.0M | not disclosed | Codexis, Inc. |
| LifeMine Biotechnology | 23 Mar 2022 | $175M | not disclosed | Fidelity Management & Research Company |
| Biotechnology | 30 Mar 2022 | $100M | not disclosed | SoftBank Vision Fund |
Sources
Where this comes from
Reported by 6 sources. The deal data marks this round as not yet confirmed by an official announcement. Unconfirmed
Questions
Frequently asked
How much did Kriya Therapeutics raise in its Series C round?
Kriya Therapeutics raised $270M in its Series C round, announced in May 2022.
Who led Kriya Therapeutics' Series C round?
Patient Square Capital led it, with Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital and T1D Fund and 4 more.
What was Kriya Therapeutics' valuation at the Series C round?
It was not disclosed.
How does it compare with other Series C rounds in Biotechnology?
46 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $86M, and this round was 3.2 times the median.
Did Kriya Therapeutics raise again after this round?
Yes: a Series D round in Sep 2025 of $320M.